|
| Tuesday, 1 October 2019, 10:46 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).
For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.
Contact:
Eisai Co., Ltd.
Media Relations
+81-(0)3-3817-5120
Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Pamela Eisele: (267) 305-3558
Kristen Drake: (908) 334-4688
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
